Argá Medtech PFA Shows 94% Durability in Burst-AF Trial
BURST-AF, a 101-patient first-in-human study of Argá Medtech’s Coherent Sine-Burst Electroporation platform, reported 100% procedural success and 94% overall...
eClinical Tech News
First Youth Enrolled in Promising Pediatric T1D Afrezza Study
MannKind has enrolled the first patient in INHALE-1ST, a U.S. multi-center, single-arm study evaluating Afrezza (inhaled human insulin) initiated...
MAPS, Columbia U Partner on First MDMA Couples Therapy Study
Enrollment targets are modest but specific: 50–100 anonymous survey responses and 10–20 confidential interviews, backed by Columbia University IRB...
Halneuron® Phase 2b Trial Reaches 50% Enrollment Milestone
Interim data from Dogwood Therapeutics’ ongoing Phase 2b HALT-CINP study point to a favorable operational and clinical signal: a...
Pulmovant Completes Enrollment for Phase 2 PH-ILD Study
In early clinical testing, a single inhaled dose of mosliciguat reduced pulmonary vascular resistance by up to 38% and...
Onward Study Offers Hope for SCI Blood Pressure Control
Feasibility data published in 2025 reported immediate, sustained increases in blood pressure with implant-based spinal cord stimulation in people...
New Trial Data: Comparable Survival Despite Genetic Mismatch
One-year overall survival exceeded 80% across all mismatch levels in the prospective, 268-patient ACCESS trial of mismatched unrelated donor...
Pivotal DEVOTE Study Results on High-Dose Nusinersen in SMA
Treatment-naïve infants with SMA receiving Biogen’s higher-dose nusinersen regimen achieved a 26.19-point advantage on CHOP-INTEND versus a prespecified matched...
First Patient Enrolled in Japan Prostate Cancer Trial
Global Phase 3 data for 177Lu‑PSMA‑I&T have met the primary endpoint with statistically significant, clinically meaningful benefit in metastatic...
Neomorph Doses First Patient in NEO-811 Cancer Trial
Neomorph has opened dosing in its first-in-human Phase 1/2 study of NEO-811, an oral, cereblon-dependent molecular glue degrader being...